View Financial HealthHantech Bio-Technology 配当と自社株買い配当金 基準チェック /36Hantech Bio-Technology配当を支払う会社であり、現在の利回りは4.42%で、収益によって十分にカバーされています。主要情報4.4%配当利回り0.6%バイバック利回り総株主利回り5.0%将来の配当利回りn/a配当成長60.0%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向61%最近の配当と自社株買いの更新Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).すべての更新を表示Recent updatesValuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.お知らせ • Mar 04Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county TaiwanBoard Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.Reported Earnings • Sep 16Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m).Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).Reported Earnings • May 16First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024)First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue.New Risk • Apr 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m).Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year.Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023)Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.お知らせ • Mar 08Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county TaiwanNew Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m).New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m).Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year.Buy Or Sell Opportunity • Oct 11Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%.Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year.New Risk • Sep 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m).New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change).New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding).New Risk • Jul 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m).New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change).New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m).New Risk • Jul 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).決済の安定と成長配当データの取得安定した配当: 配当金の支払いは安定していますが、 1294が配当金を支払っている期間は 10 年未満です。増加する配当: 1294の配当金は増加していますが、同社は3年間しか配当金を支払っていません。配当利回り対市場Hantech Bio-Technology 配当利回り対市場1294 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (1294)4.4%市場下位25% (TW)1.5%市場トップ25% (TW)5.1%業界平均 (Personal Products)5.7%アナリスト予想 (1294) (最長3年)n/a注目すべき配当: 1294の配当金 ( 4.42% ) はTW市場の配当金支払者の下位 25% ( 1.54% ) よりも高くなっています。高配当: 1294の配当金 ( 4.42% ) はTW市場の配当金支払者の上位 25% ( 5.08% ) と比較すると低いです。株主への利益配当収益カバレッジ: 1294の配当金は、合理的な 配当性向 ( 60.6% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: 1294は合理的な 現金配当性向 ( 60.5% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YTW 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/08 20:47終値2026/08/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hantech Bio-Technology Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Hsiu Chi LinMasterlink Securities Investment AdvisoryKyeongkeun KangNH Investment & Securities Co., Ltd.
Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).
Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).
Valuation Update With 7 Day Price Move • Jul 02Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$66.00, the stock trades at a trailing P/E ratio of 13.4x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total loss to shareholders of 8.9% over the past three years.
Upcoming Dividend • Jun 28Upcoming dividend of NT$3.00 per shareEligible shareholders must have bought the stock before 03 July 2026. Payment date: 31 July 2026. Payout ratio is a comfortable 61% and this is well supported by cash flows. Trailing yield: 3.8%. Lower than top quartile of Taiwanese dividend payers (5.0%). Lower than average of industry peers (5.5%).
Declared Dividend • Jun 13Dividend of NT$3.00 announcedShareholders will receive a dividend of NT$3.00. Ex-date: 3rd July 2026 Payment date: 31st July 2026 Dividend yield will be 3.8%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is covered by both earnings (61% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 70% per year over the past 3 years and payments have been stable during that time. Earnings per share has grown by 15% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Reported Earnings • May 15First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: NT$228.1m (up 31% from 1Q 2025). Net income: NT$42.7m (up 33% from 1Q 2025). Profit margin: 19% (in line with 1Q 2025).
Reported Earnings • Mar 14Full year 2025 earnings released: EPS: NT$4.60 (vs NT$5.47 in FY 2024)Full year 2025 results: EPS: NT$4.60 (down from NT$5.47 in FY 2024). Revenue: NT$778.5m (up 4.0% from FY 2024). Net income: NT$139.1m (down 11% from FY 2024). Profit margin: 18% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 42% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Mar 12Investor sentiment improves as stock rises 15%After last week's 15% share price gain to NT$91.30, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 16x in the Personal Products industry in Taiwan. Total returns to shareholders of 213% over the past three years.
お知らせ • Mar 04Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 20, 2026. Location: 1 floor no,101, kung yeh rd., sihu township, changhua county Taiwan
Board Change • Feb 25Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 3 highly experienced directors. 3 independent directors (6 non-independent directors). Independent Director Qinglong Xie was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 15Third quarter 2025 earnings released: EPS: NT$1.00 (vs NT$1.54 in 3Q 2024)Third quarter 2025 results: EPS: NT$1.00 (down from NT$1.54 in 3Q 2024). Revenue: NT$195.7m (down 1.4% from 3Q 2024). Net income: NT$30.8m (down 28% from 3Q 2024). Profit margin: 16% (down from 22% in 3Q 2024). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 34% per year, which means it is tracking significantly ahead of earnings growth.
Reported Earnings • Sep 16Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.67 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.67 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.
Reported Earnings • Aug 15Second quarter 2025 earnings released: EPS: NT$1.27 (vs NT$1.66 in 2Q 2024)Second quarter 2025 results: EPS: NT$1.27 (down from NT$1.66 in 2Q 2024). Revenue: NT$194.5m (down 10% from 2Q 2024). Net income: NT$38.6m (down 17% from 2Q 2024). Profit margin: 20% (down from 21% in 2Q 2024). The decrease in margin was driven by lower revenue.
New Risk • Jul 08New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 42% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (42% increase in shares outstanding). Minor Risk Market cap is less than US$100m (NT$2.01b market cap, or US$69.1m).
Upcoming Dividend • Jul 08Upcoming dividend of NT$3.13 per shareEligible shareholders must have bought the stock before 15 July 2025. Payment date: 11 August 2025. Payout ratio is a comfortable 56% and this is well supported by cash flows. Trailing yield: 4.5%. Lower than top quartile of Taiwanese dividend payers (5.3%). Lower than average of industry peers (5.0%).
Reported Earnings • May 16First quarter 2025 earnings released: EPS: NT$1.17 (vs NT$1.41 in 1Q 2024)First quarter 2025 results: EPS: NT$1.17 (down from NT$1.41 in 1Q 2024). Revenue: NT$174.7m (down 2.9% from 1Q 2024). Net income: NT$32.2m (down 9.7% from 1Q 2024). Profit margin: 18% (down from 20% in 1Q 2024). The decrease in margin was driven by lower revenue.
New Risk • Apr 12New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 3.6% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (NT$2.45b market cap, or US$75.8m).
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to NT$78.50, the stock trades at a trailing P/E ratio of 13.9x. Average forward P/E is 17x in the Personal Products industry in Taiwan. Total loss to shareholders of 64% over the past year.
Reported Earnings • Apr 02Full year 2024 earnings released: EPS: NT$6.02 (vs NT$5.90 in FY 2023)Full year 2024 results: EPS: NT$6.02 (up from NT$5.90 in FY 2023). Revenue: NT$748.4m (up 20% from FY 2023). Net income: NT$155.7m (up 5.1% from FY 2023). Profit margin: 21% (down from 24% in FY 2023). The decrease in margin was driven by higher expenses.
お知らせ • Mar 08Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025Hantech Bio-Technology Co., Ltd., Annual General Meeting, May 29, 2025. Location: no,101, kung yeh, sihu township, changhua county Taiwan
New Risk • Dec 06New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.9% average weekly change). High level of non-cash earnings (45% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$77.0m).
New Risk • Nov 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 9.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (9.6% increase in shares outstanding). Market cap is less than US$100m (NT$2.49b market cap, or US$76.9m).
Valuation Update With 7 Day Price Move • Oct 16Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to NT$95.50, the stock trades at a trailing P/E ratio of 13.5x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 38% over the past year.
Buy Or Sell Opportunity • Oct 11Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 35% to NT$105. The fair value is estimated to be NT$143, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 68% over the last year. Earnings per share has grown by 80%.
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to NT$118, the stock trades at a trailing P/E ratio of 16.6x. Average trailing P/E is 17x in the Personal Products industry in Taiwan. Total returns to shareholders of 61% over the past year.
New Risk • Sep 28New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.10b (US$98.3m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.7% average weekly change). Market cap is less than US$100m (NT$3.10b market cap, or US$98.3m).
New Risk • Sep 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (62% accrual ratio). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (7.6% average weekly change).
New Risk • Aug 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 15% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (60% accrual ratio). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (15% increase in shares outstanding).
New Risk • Jul 11New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: NT$3.23b (US$99.4m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (NT$3.23b market cap, or US$99.4m).
New Risk • Apr 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (9.0% average weekly change).
New Risk • Feb 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Taiwanese stocks, typically moving 5.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (5.9% average weekly change). Market cap is less than US$100m (NT$2.63b market cap, or US$83.9m).
New Risk • Jul 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Taiwanese stocks, typically moving 7.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (7.8% average weekly change). Minor Risk Market cap is less than US$100m (NT$2.28b market cap, or US$72.8m).